Inclusion Criteria:  Patients included in the PK-E3i clinical study OR Over the age of 18 Patients with hemopathies and starting treatment with oral therapy (idelalisib, ibrutinib, venetoclax, lenalidomide, acalabrutinib…) Be able to understand the objective and the constraints related to research Patient having read the information notice and the non-objection form Social Security affiliation  Exclusion Criteria:  Pregnant women Persons under legal protection of adults Patients under judicial protection